Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

Published:2013-08 Issue:8 Volume:24 Page:1972-1979
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rahma O.E.,Duffy A.,Liewehr D.J.,Steinberg S.M.,Greten T.F.

Funder

Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research

Department of Health and Human Services

US Government

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/8/1972/13789964/mdt166.pdf

Reference65 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database;Sener;J Am Coll Surg,1999

3. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil;Burris;Eur J Cancer,1997

4. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial;Louvet;J Clin Oncol,2005

5. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study;Heinemann;Ann Oncol,2007

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment;Cancer Medicine;2024-06

2. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer;Scientific Reports;2024-05-30

3. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservational study (NAPOLEON-2);2024-03-18

4. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target;BMC Genomics;2024-02-16

5. Clinical practice guidelines for interventional treatment of pancreatic cancer;Recent Advances in Nanocarriers for Pancreatic Cancer Therapy;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3